1 available, 1 completed, 1 enrolling by invitation. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Enrolling by invitation 1 |
Follow 8-hydroxyquinazolin-4(3H)-one: new trials by email Literature Review of 8-hydroxyquinazolin-4(3H)-one trials Research Report on 8-hydroxyquinazolin-4(3H)-one
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France ATH434 - Multiple System Atrophy | Phase 2 | Enrolling by invitation | Alterity Therapeutics | 7 | 2026-10-01 | 2026-10-09 |
| Study of ATH434 in Participants with Multiple System Atrophy ATH434 dose level 1, ATH434 dose level 2, Placebo - Multiple System Atrophy | Phase 2 | Completed | Alterity Therapeutics | 77 | 2022-07-01 | 2024-12-13 |
| Post-Trial Access to ATH434 for Patients With Multiple System Atrophy ATH434 - Multiple System Atrophy | Available | Alterity Therapeutics | 2026-04-15 |
Multiple System Atrophy (3) · Movement Disorders (1) · Neurodegenerative Diseases (1) · Primary Dysautonomias (1) · Shy-Drager Syndrome (1) · Synucleinopathies (1)
France (2) · Australia (1) · Italy (1) · New Zealand (1) · United Kingdom (1) · United States (1)
2025 (1)